LGM
LRMR icon

Logos Global Management’s Larimar Therapeutics LRMR Stock Holding History

Logos Global Management’s Portfolio LRMR Stock Details LRMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-2,500,000
Closed -$8.07M – 79
2025
Q3 		$8.07M Hold
2,500,000
– – 0.72% 36
2025
Q2 		$7.22M Buy
+2,500,000
New +$5.79M 0.8% 37
2024
Q2 		– Sell
-700,000
Closed -$5.31M – 70
2024
Q1 		$5.31M Buy
+700,000
New +$5.45M 0.43% 46

Other funds holding LRMR

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Logos Global Management's LRMR Position: Q2 2021 in Review

Logos Global Management sold out of Larimar Therapeutics (LRMR) in Q2 2021, closing a stake of 230,000 shares — an estimated $3.36M sold.

Logos Global Management first reported a position in LRMR in Q2 2020 and held it in 4 quarters. The position peaked at $15.3M in Q4 2020. 45 funds tracked by Wall St. Rank hold LRMR as of Q2 2021.

  • Logos Global Management reported no remaining Larimar Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Logos Global Management sold 230,000 Larimar Therapeutics shares in Q2 2021, an estimated $3.36M.
  • Logos Global Management first reported a position in Larimar Therapeutics in Q2 2020 and held it in 4 quarters.
  • Logos Global Management's Larimar Therapeutics position peaked at $15.3M in Q4 2020.
  • 45 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q2 2021.

Based on Logos Global Management's 13F filing for Q2 2021, filed 16 Aug 2021.